FDA approval fraud lawsuits are securities fraud claims brought by investors against pharmaceutical and biotech companies that make misleading statements about FDA approval timelines, likelihood, or requirements. When a company publicly claims its drug is likely to receive FDA approval on a specific schedule, but then fails to disclose material information suggesting approval is unlikely, investors who relied on those statements may have grounds for legal action. Recent years have seen a significant uptick in these cases, particularly after the FDA delays the approval of drugs that company executives previously characterized as near-certain to be approved. For example, uniQure N.V.
represented to investors that its lead drug AMT-130 had a high likelihood of accelerated FDA approval by Q1 2026, but in November 2025, the FDA determined that Phase I/II data may not be adequate to support the application—a disclosure that triggered a 49% stock decline and prompted a securities fraud class action with an April 13, 2026 lead plaintiff deadline. FDA approval fraud differs from other securities fraud because it hinges on scientific and regulatory uncertainties that companies may deliberately obscure or mischaracterize. Investors in biotech companies often have limited ability to assess drug efficacy and safety data independently, which creates an asymmetry of information. When executives knowingly overstate approval odds or fail to disclose unfavorable communications with the FDA, they violate securities laws that require companies to disclose material information to investors. The resulting class actions can recover substantial damages for shareholders who purchased stock at inflated prices based on fraudulent representations.
Table of Contents
- What Constitutes FDA Approval Fraud in Securities Law?
- How Companies Misrepresent FDA Approval Prospects and Timelines
- Recent FDA Approval Fraud Cases and Their Outcomes
- Investor Rights and the Securities Class Action Process
- Red Flags That May Indicate FDA Approval Misrepresentation
- The Financial Impact of FDA Approval Fraud on Shareholders
- Lessons and Future Regulatory Trends
- Conclusion
What Constitutes FDA Approval Fraud in Securities Law?
FDA approval fraud occurs when a pharmaceutical or biotech company makes statements to investors about FDA approval prospects that are materially misleading, either because they are false or because the company omits material facts that contradict the positive statements. Under securities laws, companies have an obligation to disclose material information—information that a reasonable investor would consider important in deciding whether to buy, sell, or hold stock. Material information includes adverse communications from the FDA, clinical trial results that suggest efficacy or safety concerns, and internal company assessments that contradict public statements about approval likelihood.
The fraud element requires that the company either knowingly made false statements or recklessly disregarded the truth. A company executive cannot simply be optimistic about FDA approval prospects; there must be evidence that the company either knew its statements were false or that the company was aware of information contradicting its public claims. This is why internal communications, FDA correspondence, and clinical trial data become critical in proving FDA approval fraud. For instance, if a company’s internal emails show that executives were concerned about FDA approval prospects while publicly claiming high approval odds, that disconnect constitutes strong evidence of scienter (intent to defraud or reckless disregard for truth).
How Companies Misrepresent FDA Approval Prospects and Timelines
Pharmaceutical and biotech companies commit FDA approval fraud in several ways. The most common method is overstating approval probability while downplaying or failing to disclose unfavorable FDA communications. When the FDA issues a Complete Response Letter (CRL)—indicating that the application cannot be approved in its current form—companies may delay public disclosure or frame the CRL in misleadingly optimistic terms. Similarly, companies may claim that a drug is “on track” for approval by a specific date without disclosing that the FDA has privately communicated concerns that make that timeline unrealistic. Another form of fraud involves false or misleading promotional claims.
ImmunityBio, Inc. faced an FDA warning letter in March 2026 for making false and misleading promotional claims about its bladder cancer drug ANKTIVA in television advertisements and podcasts, claims that violated the Federal Food, Drug, and Cosmetic Act. The disclosure of the FDA warning letter caused ImmunityBio’s stock to decline 21% to $7.42 per share, and investors filed a securities fraud class action. These promotional misstatements matter legally because they suggest the company may have been making internal misrepresentations about the drug’s profile or efficacy. Companies may also selectively disclose positive clinical trial data while omitting results that show safety concerns or lack of efficacy, creating a misleading overall impression of approval likelihood.
Recent FDA Approval Fraud Cases and Their Outcomes
The past several months have produced a cluster of FDA approval fraud cases that illustrate how quickly investor confidence can evaporate when FDA approval prospects deteriorate. uniQure N.V.’s securities fraud case is one of the most dramatic examples. The company had represented that its lead drug AMT-130 for Huntington’s disease had a high likelihood of receiving accelerated FDA approval in the first quarter of 2026. However, on November 3, 2025, uniQure disclosed that the FDA had determined Phase I/II data may not be adequate to support the Biologics License Application. That single announcement triggered a 49% stock price decline—from $67.69 to $34.29 per share—and a securities fraud class action lawsuit.
The lead plaintiff deadline in that case is April 13, 2026. Corcept Therapeutics faced a similar reversal when the FDA issued a Complete Response Letter for relacorilant on December 31, 2025, stating that the FDA could not arrive at a favorable benefit-risk assessment without additional evidence of effectiveness. Corcept’s stock plummeted 50.4% ($35.40 per share), and the company became the subject of a securities fraud class action. These cases share a common pattern: executives’ prior statements about approval were sufficiently specific and optimistic that when the FDA rejected the application, investors felt misled. Aquestive Therapeutics faced a 37% one-day stock decline (from $6.21 to $3.91 per share) on January 9, 2026, when it became apparent that its drug Anaphylm would not receive FDA approval by the claimed January 31, 2026 deadline. The company had previously claimed the drug was “on track” for that approval date, but the FDA had identified deficiencies that precluded label discussions.
Investor Rights and the Securities Class Action Process
If you purchased stock in a biotech company that made misleading statements about FDA approval and your losses were material, you may have rights as a member of a securities fraud class action. These actions are structured so that individual investors do not have to file separate lawsuits; instead, a lead plaintiff (the investor or group of investors with the largest losses) represents the entire class. Settlements in pharmaceutical fraud cases can range from millions to tens of millions of dollars, depending on the number of affected investors, the trading volume, and the strength of evidence of fraud.
The timeline for joining a securities fraud class action typically includes a lead plaintiff deadline (by which point investors must decide whether to serve as the named plaintiff), followed by motion-to-dismiss briefing, discovery, and settlement negotiations or trial. For example, ImmunityBio’s case has a May 26, 2026 lead plaintiff deadline, meaning investors have until that date to decide whether to take on the role of lead plaintiff. Even if you do not become the lead plaintiff, you can still be part of the class action and receive a distribution from any settlement. To qualify, you generally must have purchased the company’s stock during a specific period (the “class period”), which is typically defined as the time between when the company made its false statements and when the truth was disclosed.
Red Flags That May Indicate FDA Approval Misrepresentation
Certain warning signs suggest that a company may be misrepresenting its FDA approval prospects. First, be wary of very specific approval timelines combined with language such as “on track,” “expected,” or “likely.” Companies using this language are making predictive statements, and if those predictions prove inaccurate, they may face fraud liability. If a company’s executives use increasingly confident language about approval as the FDA review process proceeds—rather than acknowledging that regulatory outcomes are inherently uncertain—that shift in tone can signal overconfidence or deliberate misstatement. Second, watch for delays in disclosing adverse FDA communications. If a company receives an FDA warning letter or complete response letter, securities laws require prompt public disclosure.
Aquestive’s case illustrates this risk: the company claimed Anaphylm was on track for January 31, 2026 approval, but the FDA had already identified deficiencies that made that timeline impossible. The gap between the company’s public statements and the reality of the FDA’s position created liability. Third, pay attention to the relationship between the company’s promotional and regulatory statements. If the company is making aggressive marketing claims about a drug that has not yet been approved, the FDA may view those claims as violations of regulations, as occurred with ImmunityBio’s ANKTIVA advertisement. Such regulatory violations often signal that the company has been overreaching in its representations about the drug.
The Financial Impact of FDA Approval Fraud on Shareholders
The financial consequences of FDA approval fraud can be severe and immediate. When approval is denied or delayed, biotech stocks often experience sharp, sudden declines because the market reprices the company based on the loss of expected revenue from the delayed or rejected drug. These declines hit retail and institutional investors alike, but small investors often suffer disproportionately because they lack the resources to exit quickly or to hedge their exposure. The declines seen in recent cases—ranging from 21% for ImmunityBio to 50% for Corcept Therapeutics to 49% for uniQure—are not gradual corrections but rather sudden repricing events that occur when the truth about FDA approval prospects emerges.
The severity of the stock decline is also the primary metric that determines the size of potential class action recovery. A company that loses 50% of its market value due to a misrepresented FDA approval provides significantly more potential recovery to investors than a company with a modest decline. This is because the damages calculation in a securities class action is generally based on the “inflation” in the stock price caused by the fraudulent misstatement. If a stock was artificially elevated by $30 per share due to false FDA approval claims, investors who purchased during that inflated period may recover a portion of that $30 per share loss.
Lessons and Future Regulatory Trends
The recent wave of FDA approval fraud cases suggests several trends for investors and companies going forward. First, the FDA and SEC are clearly coordinating more closely to identify companies making false or misleading statements about drug development. Favorable communications from the FDA (such as fast-track designations or breakthrough therapy designations) do not guarantee approval, and companies that use these designations to overstate approval likelihood face regulatory and securities law consequences.
Second, biotech companies are increasingly vulnerable to fraud liability if they make any specific claims about approval timelines or odds, because regulatory outcomes are inherently uncertain and market participants are highly sensitive to approval news. For investors, this environment underscores the importance of reading SEC filings carefully, paying attention to the actual language companies use about FDA approval prospects (particularly whether they use hedging language such as “if approved” or “subject to FDA review”), and monitoring FDA communications and clinical trial disclosures. Many securities fraud law firms now specialize in biotech cases and can evaluate whether a company’s statements crossed the line from optimistic to fraudulent, often at no upfront cost to the investor.
Conclusion
FDA approval fraud lawsuits protect investors from biotech and pharmaceutical companies that knowingly or recklessly overstate the likelihood, timing, or certainty of FDA approval for their drugs. Recent cases involving uniQure, Corcept Therapeutics, ImmunityBio, and Aquestive Therapeutics demonstrate that when companies make materially misleading statements about FDA approval prospects and then face regulatory setbacks, shareholders can pursue class action lawsuits and recover damages.
These cases typically involve stock declines of 20% to 50% or more and settlements that distribute recovered funds to affected shareholders. If you purchased stock in a biotech or pharmaceutical company that made specific claims about FDA approval timelines or odds, and the company subsequently announced that the FDA has denied approval, delayed approval significantly, or issued a warning letter, you should consider consulting with a securities attorney about your potential class action rights. Most class action settlements have claim deadlines, so it is important to investigate your eligibility promptly and understand the lead plaintiff deadline for any case that may cover your purchases.